The Genetics Company Enters Distribution Agreement with Prodotti Gianni
Advertisement
The Genetics Company, Inc. announced that it has entered a distribution agreement with Prodotti Gianni s.p.a., a leading Italian distributor of life science research reagents and instruments, cosmetic constituents and food ingredients. Within the scope of this agreement The Genetics Company will supply Prodotti Gianni s.p.a. with its innovative Alzheimer's disease diagnostic products and research tools for distribution within Italy.
The Genetics Company's Alzheimer's disease diagnostic products and research tools enable the highly specific and selective detection of variants of human beta-Amyloid, a key protein associated with the pathogenesis of Alzheimer's disease. The Company's products include a very sensitive and reliable ELISA based kit for the quantification of beta-Amyloid 40 and 42 peptides in cerebrospinal fluid of patients (CSF ELISA), a method which already has been and continues to be validated in clinical trials and which emerges as an indispensable part of the Alzheimer's disease diagnosis process in patients.
A high sensitivity research version of these test kits, especially designed for the detection of beta- Amyloid 40 and 42 peptides in cell supernatants, brain lysates and other matrices, is also available for use in preclinical and clinical research. These ELISA test kits are complemented by superior quality antibodies for the detection of beta-Amyloid 40 and 42. These products already enjoy a considerable success on the Italian market and will now be distributed by Prodotti Gianni s.p.a., a major distributor of innovative diagnostic products and reagents in Italy.
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous